APA

Mantovani L., Hasenclever D., Krahl R., Pönisch W., Herold M., Pasold R., Fiedler F., Dölken G., Kämpfe D., Schmoll H. J., Súbert R., Kubel M., Niederwieser D. & Helbig W. (20030711). Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. : Leukemia & lymphoma.

Chicago

Mantovani Luisa, Hasenclever Dirk, Krahl Rainer, Pönisch Wolfram, Herold Michael, Pasold Rita, Fiedler Friedrich, Dölken Gottfried, Kämpfe Dietrich, Schmoll Hans Joachim, Súbert Rita, Kubel Martin, Niederwieser Dietger and Helbig Werner. 20030711. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. : Leukemia & lymphoma.

Harvard

Mantovani L., Hasenclever D., Krahl R., Pönisch W., Herold M., Pasold R., Fiedler F., Dölken G., Kämpfe D., Schmoll H. J., Súbert R., Kubel M., Niederwieser D. and Helbig W. (20030711). Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. : Leukemia & lymphoma.

MLA

Mantovani Luisa, Hasenclever Dirk, Krahl Rainer, Pönisch Wolfram, Herold Michael, Pasold Rita, Fiedler Friedrich, Dölken Gottfried, Kämpfe Dietrich, Schmoll Hans Joachim, Súbert Rita, Kubel Martin, Niederwieser Dietger and Helbig Werner. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. : Leukemia & lymphoma. 20030711.